# Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD

> **NCT05170048** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Evergreen Therapeutics, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)

## Interventions

- **DRUG:** EG-301
- **DIETARY_SUPPLEMENT:** AREDS2 supplements

## Key facts

- **NCT ID:** NCT05170048
- **Lead sponsor:** Evergreen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05170048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05170048, "Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05170048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*